(secondQuint)Five Year Adjuvant Imatinib Mesylate (Gleevec) in Gastrointestinal Stromal Tumor (GIST).

 This is a Phase II, non-randomized, open-label, multi-center study conducted in the USA.

 The primary endpoint is to evaluate the use of long term adjuvant imatinib mesylate in patients at significant risk for recurrence following complete resection of primary GIST.

 A total of 85 adult patients, 18 years of age and older will be enrolled.

Participants will take 400 mg of imatinib mesylate daily by mouth for a total of 5 years.

 At the conclusion of the treatment period, patients will be followed for 2 years for survival, status of response and antineoplastic treatments and quality of life.

.

 Five Year Adjuvant Imatinib Mesylate (Gleevec) in Gastrointestinal Stromal Tumor (GIST)@highlight

This is a Phase II, non-randomized, open-label, multi-center study conducted in the USA.

 The purpose of this trial is to evaluate the use of long term adjuvant imatinib mesylate in patients at significant risk for recurrence following complete resection of primary GIST.

